Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  CRISPR Therapeutics AG    CRSP   CH0334081137

CRISPR THERAPEUTICS AG

(CRSP)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/11/2021 01/12/2021 01/13/2021 01/14/2021 01/15/2021 Date
188.88(c) 190.34(c) 193.84(c) 210.04(c) 199.88(c) Last
2 716 841 2 072 202 1 733 424 2 723 891 4 004 905 Volume
-2.55% +0.77% +1.84% +8.36% -4.84% Change
More quotes
Financials (USD)
Sales 2020 2,60 M - -
Net income 2020 -330 M - -
Net cash position 2020 1 213 M - -
P/E ratio 2020 -39,9x
Yield 2020 -
Sales 2021 14,3 M - -
Net income 2021 -383 M - -
Net cash position 2021 1 037 M - -
P/E ratio 2021 -37,6x
Yield 2021 -
Capitalization 14 233 M 14 233 M -
EV / Sales 2020 5 008x
EV / Sales 2021 920x
Nbr of Employees 304
Free-Float 82,8%
More Financials
Company
CRISPR Therapeutics AG is a Switzerland-based gene-editing company. It focuses on the development of transformative gene-based medicines for serious diseases. The Company develops its products using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform, which allows for precise directed changes to genomic deoxyribonucleic acid (DNA). The Company has a portfolio of therapeutic... 
More about the company
Notations Surperformance© of CRISPR Therapeutics AG
Trading Rating : Investor Rating :
More Ratings
All news about CRISPR THERAPEUTICS AG
01/15CRISPR THERAPEUTICS : Plans Share Offering of up to $600 Million
MT
01/04CRISPR THERAPEUTICS : Corporate Presentation
PU
2020CRISPR THERAPEUTICS : Insider Selling at CRISPR Therapeutics (CRSP) Continues wi..
MT
2020INSIDER TRENDS : CRISPR Therapeutics Insider Continues 90-Day Selling Trend
MT
2020CRISPR THERAPEUTICS : CRSP) Insider Makes Significant Share Sale
MT
2020INSIDER TRENDS : 90-Day Insider Selling Trend Prolonged at CRISPR Therapeutics
MT
2020CRISPR THERAPEUTICS : Gets Funding to Develop in Vivo Crispr/Cas9 Gene Editing T..
MT
2020CRISPR Therapeutics Receives Grant to Advance In Vivo CRISPR/Cas9 Gene Editin..
GL
2020CRISPR THERAPEUTICS : Plans Offering of up to $350 Million
MT
2020CRISPR THERAPEUTICS : Insider at CRISPR Therapeutics (CRSP) Makes Significant Sa..
MT
2020INSIDER TRENDS : Insider at CRISPR Therapeutics Reports Option Conversion Amid 9..
MT
2020CRISPR THERAPEUTICS : Piper Sandler Adjusts Price Target on CRISPR Therapeutics ..
MT
2020CRISPR THERAPEUTICS : Oppenheimer Adjusts CRISPR Therapeutics' Price Target to $..
MT
2020Needham Adjusts CRISPR Therapeutics' Price Target to $170 From $105, Keeps at..
MT
2020Jefferies Downgrades CRISPR Therapeutics AG to Hold From Buy, Lifts PT to $15..
MT
More news
News in other languages on CRISPR THERAPEUTICS AG
01/11STRATÉGIE : les quatre meilleurs fonds US 2020
2020BB Biotech renoue avec les bénéfices en 2019
2017BIOTECHNOLOGIES : revenus en hausse pour le secteur à 5,7 mrd CHF en 2016
2017BIOTECHNOLOGIES : revenus en hausse pour le secteur à 5,7 mrd CHF en 2016
More news
Analyst Recommendations on CRISPR THERAPEUTICS AG
More recommendations
Chart CRISPR THERAPEUTICS AG
Duration : Period :
CRISPR Therapeutics AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CRISPR THERAPEUTICS AG
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 18
Average target price 146,56 $
Last Close Price 199,88 $
Spread / Highest target 5,06%
Spread / Average Target -26,7%
Spread / Lowest Target -77,5%
EPS Revisions
Managers and Directors
NameTitle
Samarth Kulkarni Chief Executive Officer & Director
Rodger Novak Chairman & President
Lawrence O. Klein Chief Operating & Business Officer
Michael John Tomsicek CFO & Principal Accounting Officer
Tony W. Ho Executive VP, Head-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
CRISPR THERAPEUTICS AG30.55%14 233
MODERNA, INC.24.10%51 304
LONZA GROUP AG3.27%49 041
CELLTRION, INC.-12.53%40 715
IQVIA HOLDINGS INC.4.81%36 004
SEAGEN INC.6.06%33 601